Table 3.

irAEs.

	Grade 1	Grade 2	Grade 3	Grade 4
Neoadjuvant (n = 31)
Diarrhea/colitis	6 (19.4%)	0	1 (3.2%)	0
Rash	3 (9.7%)	2 (6.5%)	0	0
AST/ALT increased	1 (3.2%)	0	0	0
Endocrinopathya	1 (3.2%)	0	1 (3.2%)	0
Hemolysis	0	0	1 (3.2%)	0
Myocarditisb	0	0	0	1 (3.2%)
CNS palsy	0	1 (3.2%)	0	0
Adjuvant (n = 21)
Diarrhea/colitis	10 (47.6%)	1 (4.8%)	0	0
Rash	3 (14.3%)	1 (4.8%)	0	0
AST/ALT increased	1 (4.8%)	1 (4.8%)	3 (14.3%)	0
Endocrinopathyc	1 (4.8%)	0	0	0
Palpitations	0	1 (4.8%)	0	0
Cholecystitis	0	0	1 (4.8%)	0

^aHypophysitis.

^bThe patient who developed grade 4 myocarditis presented with a complete heart block and sustained ventricular tachycardia after receiving two doses of neoadjuvant pembrolizumab. His symptoms persisted despite high-dose steroid, amiodarone and flecainide drip treatment, and dual chamber pacer, which finally and immediately resolved after plasma exchange. His left ventricular ejection fraction was maintained at about 50% throughout.

^cHyperglycemia.